HNH
GALT icon

Hopwood Nicholas Hunter’s Galectin Therapeutics GALT Stock Holding History

Hopwood Nicholas Hunter’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193K Hold
69,295
– – 0.06% 120
2025
Q4 		$288K Buy
+69,295
New +$365K 0.09% 109

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Hopwood Nicholas Hunter's GALT Position: Q1 2026 in Review

Hopwood Nicholas Hunter held its Galectin Therapeutics (GALT) position steady in Q1 2026 at 69,295 shares worth $193K. The position accounts for 0.06% of the portfolio, ranked #120.

Hopwood Nicholas Hunter first reported a position in GALT in Q4 2025 and has held it in 2 quarters since. The position peaked at $288K in Q4 2025. 99 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Hopwood Nicholas Hunter held 69,295 shares of Galectin Therapeutics worth $193K as of Q1 2026.
  • Hopwood Nicholas Hunter left its Galectin Therapeutics share count unchanged in Q1 2026.
  • Galectin Therapeutics made up 0.06% of Hopwood Nicholas Hunter's portfolio in Q1 2026, its #120 holding.
  • Hopwood Nicholas Hunter first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Hopwood Nicholas Hunter's Galectin Therapeutics position peaked at $288K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Hopwood Nicholas Hunter's 13F filing for Q1 2026, filed 14 Aug 2026.